Obsidian Therapeutics, Inc. (OBX)
11.24
+1.64
(+17.08%)
USD |
NASDAQ |
Nov 06, 10:17
Obsidian Therapeutics Enterprise Value : 299.55M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 299.55M |
| November 04, 2026 | 299.71M |
| November 03, 2026 | 299.96M |
| November 02, 2026 | 300.09M |
| October 30, 2026 | 300.13M |
| October 29, 2026 | 300.10M |
| October 28, 2026 | 300.11M |
| October 27, 2026 | 300.07M |
| October 26, 2026 | 300.03M |
| October 23, 2026 | 300.04M |
| October 22, 2026 | 300.03M |
| October 21, 2026 | 300.03M |
| October 20, 2026 | 299.96M |
| October 19, 2026 | 299.81M |
| October 16, 2026 | 299.79M |
| October 15, 2026 | 299.84M |
| October 14, 2026 | 299.84M |
| October 13, 2026 | 299.82M |
| October 12, 2026 | 299.91M |
| October 09, 2026 | 299.93M |
| October 08, 2026 | 299.85M |
| October 07, 2026 | 299.95M |
| October 06, 2026 | 299.96M |
| October 05, 2026 | 300.02M |
| October 02, 2026 | 300.00M |
| Date | Value |
|---|---|
| October 01, 2026 | 299.97M |
| September 30, 2026 | 300.01M |
| September 29, 2026 | 300.11M |
| September 28, 2026 | 299.97M |
| September 25, 2026 | 299.92M |
| September 24, 2026 | 299.98M |
| September 23, 2026 | 300.18M |
| September 22, 2026 | 300.37M |
| September 21, 2026 | 300.41M |
| September 18, 2026 | 300.46M |
| September 17, 2026 | 300.43M |
| September 16, 2026 | 300.39M |
| September 15, 2026 | 300.37M |
| September 14, 2026 | 300.50M |
| September 11, 2026 | 300.46M |
| September 10, 2026 | 300.39M |
| September 09, 2026 | 300.56M |
| September 08, 2026 | 300.57M |
| September 04, 2026 | 300.35M |
| September 03, 2026 | 300.38M |
| September 02, 2026 | 300.37M |
| September 01, 2026 | 300.38M |
| August 31, 2026 | 300.43M |
| August 28, 2026 | 300.30M |
| August 27, 2026 | 300.38M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cypherpunk Technologies, Inc. | 258.59M |
| Cue Biopharma, Inc. | 85.60M |
| Yarrow Bioscience, Inc. | -13.84M |
| Faeth Therapeutics, Inc. | 346.90M |
| Immuneering Corp. | 76.38M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -25.86M |
| Total Expenses (Quarterly) | 25.86M |
| EPS Diluted (Quarterly) | -237.20 |
| Earnings Yield | 1.44K% |
| Normalized Earnings Yield | -1106.83 |